The company is actively presenting at major investment conferences and continues to advance its portfolio with successful partnerships. Recent financial results showed 14% revenue growth, and subsidiary Urica Therapeutics' partner Crystalys Therapeutics secured $130 million in Series B financing, indicating strong momentum and investor confidence in the company's business model and assets.
Also mentions FBIO
Articles that tag FBIO but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
